Spontaneous Bacterial Peritonitis (SBP)
Spontaneous bacterial peritonitis (SBP) is a life-threatening infection of ascitic fluid that occurs without an obvious surgically correctable source, such as a perforated bowel. It is a defining complication of decompensated cirrhosis — arising in 10–30% of hospitalized cirrhotics with ascites — and carries an in-hospital mortality of 20–30% even with prompt treatment. The name "spontaneous" distinguishes it from secondary bacterial peritonitis (caused by intra-abdominal pathology), but it is anything but spontaneous: it is the predictable result of gut bacterial translocation into a peritoneal fluid that lacks the immune defenses needed to clear an infection.
- Overview and Epidemiology
- Pathophysiology: Bacterial Translocation
- Causative Organisms
- Clinical Presentation
- Diagnosis: The Diagnostic Paracentesis
- Distinguishing Secondary Bacterial Peritonitis
- Treatment
- Albumin Infusion: Preventing Kidney Injury
- Prophylaxis and Prevention
- Prognosis and Long-Term Outlook
- Key Research Papers
- Connections
Overview and Epidemiology
SBP occurs almost exclusively in patients with cirrhosis and ascites — the portal hypertension-driven accumulation of fluid in the peritoneal cavity. It is rare in other causes of ascites (e.g., heart failure, cancer) because the ascitic protein and complement levels in those conditions are typically higher, providing some immune barrier. In cirrhotic ascites, total protein is often below 15 g/L, and levels of complement C3 and opsonins are severely reduced, leaving the fluid defenseless against bacteria that translocate from the gut.
The annual incidence of SBP in outpatients with cirrhosis and ascites is 1.5–3.5%, rising sharply to 10–30% in hospitalized patients. The 1-year recurrence rate after a first episode of SBP, without prophylaxis, exceeds 40–70%. One-year mortality after a first SBP episode is approximately 30–50%, reflecting the severity of the underlying liver disease — SBP marks a transition to late-stage decompensated cirrhosis.
Risk factors for SBP include: low ascitic fluid total protein (<15 g/L), prior episode of SBP, acute gastrointestinal hemorrhage, Child-Pugh class C, serum bilirubin >3 mg/dL, and renal impairment.
Stomach-acid-lowering drugs (proton pump inhibitors) have also been linked to SBP. A 2021 meta-analysis of 23 studies and 10,386 patients found a pooled odds ratio of 1.80, weaker at 1.55 in cohort studies, with substantial differences between studies and signs of publication bias; its authors describe the association as weak.
Pathophysiology: Bacterial Translocation
SBP develops through a three-step cascade: bacterial translocation → bacteremia → peritoneal infection.
Step 1 — Gut bacterial overgrowth and translocation: Cirrhosis alters gut motility, increases intestinal permeability ("leaky gut"), and disrupts the mucosal immune barrier. Intestinal bacterial overgrowth (small intestinal bacterial overgrowth, SIBO) is common. Bacteria — predominantly enteric gram-negatives — breach the intestinal epithelium and enter mesenteric lymph nodes. In a healthy liver, the reticuloendothelial system (Kupffer cells) would clear these organisms from portal blood. In cirrhosis, Kupffer cell function is impaired and portosystemic shunting bypasses the hepatic filter entirely, allowing bacteremic spillover into systemic circulation.
Step 2 — Bacteremia: Transient or sustained bacteremia seeds the peritoneal fluid. The route is hematogenous, not direct spread from bowel.
Step 3 — Failure of peritoneal host defense: Cirrhotic ascitic fluid has critically low opsonic activity. Complement C3 levels in ascites correlate inversely with SBP risk — patients with ascitic C3 below 13 mg/dL have a dramatically higher rate of infection. Without opsonization, neutrophils cannot effectively phagocytose and kill bacteria. The infection amplifies unchecked, triggering a systemic inflammatory response that precipitates acute kidney injury (hepatorenal physiology) and worsens hepatic encephalopathy.
Why albumin infusion works: Albumin is not just a volume expander. It binds bacterial lipopolysaccharide (LPS) and other inflammatory mediators, modulates systemic vasodilation, and directly supports renal perfusion. This mechanism underpins why albumin co-administration with antibiotics reduces mortality — the antibiotic kills the bacteria but the inflammatory cascade from lipopolysaccharide release still harms the kidneys without albumin buffering.
Causative Organisms
SBP is predominantly caused by enteric organisms reflecting the gut-translocation route. Approximately 70% of SBP cases involve gram-negative bacilli:
- Escherichia coli: most common, ~40% of cases
- Klebsiella pneumoniae: second most common gram-negative, ~15%
- Other Enterobacteriaceae: Enterobacter, Proteus species
- Streptococcus pneumoniae: most common gram-positive organism (~15%); associated with a milder form, better prognosis
- Streptococcus viridans and other streptococci
- Staphylococcus aureus: less common; raises suspicion for secondary peritonitis or catheter-related infection
- Anaerobes and fungi: rare in SBP; their presence strongly suggests secondary bacterial peritonitis (bowel perforation)
Cultures are negative in approximately 40% of cases despite the ascitic neutrophil count meeting diagnostic criteria — these cases are called "culture-negative neutrocytic ascites" (CNNA) and carry the same prognosis and treatment as culture-positive SBP. Inoculating ascitic fluid directly into blood culture bottles at bedside (10 mL per bottle) significantly improves culture yield compared to sending fluid to the lab in sterile tubes.
Multidrug-resistant (MDR) organisms: MDR-SBP is an emerging problem, particularly in patients with prior antibiotic exposure, healthcare-associated infections, or who live in regions with high MDR prevalence. Third-generation cephalosporins (cefotaxime/ceftriaxone) have an 85–90% success rate in community-acquired SBP; MDR organisms require carbapenem therapy.
Clinical Presentation
The classic triad — fever, abdominal pain, and altered mental status — occurs in fewer than 50% of patients with SBP. Many patients, especially those with severe liver disease and hepatic encephalopathy as a baseline, present atypically or are entirely asymptomatic, discovered only because a diagnostic paracentesis is performed as standard of care.
Symptoms and signs when present:
- Fever: temperature >37.8°C in ~50–70%; hypothermia (poor prognosis) can also occur
- Abdominal pain or tenderness: ~50–60%; often diffuse, but can be mild and non-localizing because ascites cushions peritoneal stretch; the dramatic board-like rigidity of secondary peritonitis (bowel perforation) is typically absent
- Worsening hepatic encephalopathy: a key clinical clue — any acute deterioration in mental status in a person with cirrhosis and ascites is a recognized reason for paracentesis
- Worsening renal function: rising creatinine accompanying or following SBP; ~30% develop acute kidney injury
- Worsening ascites or reduced response to diuretics
- Gastrointestinal (GI) symptoms: nausea, vomiting, diarrhea — non-specific
- Asymptomatic: up to 30–40% in some series; diagnosed only by routine admission paracentesis
What liver-society guidelines state: Guidelines call for diagnostic paracentesis in every person with cirrhosis admitted to hospital with ascites, regardless of symptoms, and whenever any clinical deterioration occurs (new encephalopathy, fever, abdominal pain, rising creatinine, or leukocytosis). Waiting for symptoms leads to delayed diagnosis and increased mortality.
In a two-center study of 239 hospital patients with SBP, those whose fluid was sampled 12 to 72 hours after admission died in hospital more often than those sampled within 12 hours (27% vs. 13%). Each hour of delay was associated with a 3.3% rise in in-hospital deaths after adjusting for the Model for End-Stage Liver Disease (MELD) score and creatinine.
Diagnosis: The Diagnostic Paracentesis
SBP is diagnosed by analysis of ascitic fluid obtained by paracentesis. The key diagnostic value is the ascitic fluid polymorphonuclear leukocyte (PMN) count — not the culture result.
SBP diagnostic criteria:
- Ascitic fluid PMN count ≥250 cells/μL — this is sufficient to diagnose SBP and begin antibiotics, regardless of culture result
- Culture-positive SBP: PMN ≥250 + positive culture
- Culture-negative neutrocytic ascites (CNNA): PMN ≥250 + negative culture — treated the same way as culture-positive SBP
- Bacterascites: PMN <250 + positive culture — may represent early/transient bacteremia or lab contamination; clinical judgment required; often resolves spontaneously but warrants close monitoring and repeat paracentesis
Ascitic fluid appearance: typically cloudy in SBP; turbid to frankly purulent in secondary peritonitis. Bloody ascites (traumatic tap or hepatocellular carcinoma, a liver cancer) requires correcting the PMN count: subtract 1 PMN per 250 red blood cells.
Additional ascitic fluid tests:
- Total protein: low (<10–15 g/L) in SBP; high (>10–15 g/L) in secondary peritonitis
- Glucose: normal or mildly low in SBP; very low (<50 mg/dL) in secondary peritonitis
- Lactate dehydrogenase (LDH): elevated in secondary peritonitis
- Gram stain: low sensitivity (10–20%) in SBP — a negative stain does not exclude it
- Culture: blood culture bottles inoculated at bedside (10 mL aerobic + 10 mL anaerobic); culture negative in ~40% despite SBP
- Serum ascites albumin gradient (SAAG): confirms ascites is portal hypertensive (SAAG ≥1.1 g/dL) rather than exudative (malignancy, tuberculosis, pancreatitis)
Point-of-care PMN testing: Reagent strip (leukocyte esterase dipstick) testing of ascitic fluid provides a rapid bedside PMN estimate, but its accuracy varies widely. A systematic review of 17 studies found sensitivity ranging from 45% to 100%, specificity from 81% to 100%, positive predictive value from 42% to 100% and negative predictive value from 87% to 100%, too inconsistent to pool. A multicenter study of 2,123 paracenteses found 45.3% sensitivity at a 2+ threshold and concluded that the strip it tested had no diagnostic efficacy. An emergency department study at a “trace” threshold found 95% sensitivity, 48% specificity and an 11% positive predictive value, and its authors could not recommend the strip as a stand-alone test.
Distinguishing Secondary Bacterial Peritonitis
Secondary bacterial peritonitis — peritoneal infection due to a surgically correctable intra-abdominal source (perforated viscus, abscess, cholecystitis) — is distinguished from SBP because its management is surgical, not antibiotic alone. Failure to recognize secondary peritonitis and operating on a patient believed to have SBP (or vice versa) carries high mortality.
Runyon's criteria for secondary peritonitis (any 2 of 3):
- Ascitic fluid total protein >10 g/L (or >1 g/dL)
- Ascitic fluid glucose <50 mg/dL
- Ascitic fluid lactate dehydrogenase greater than the upper limit of normal serum lactate dehydrogenase
Additional features favoring secondary peritonitis: polymicrobial culture (multiple organisms), anaerobes or fungi on culture, very high PMN count (>5000/μL), loculated fluid on imaging, and failure to respond to appropriate antibiotics within 48 hours. Computed tomography (CT) of the abdomen is the urgent test used to identify the source when secondary peritonitis is suspected.
A repeat paracentesis at 48 hours is recommended in all SBP cases both to confirm treatment response (a PMN fall of >25% from baseline is the expected response) and to detect secondary peritonitis that was not initially apparent.
Treatment
Treatment of SBP has three pillars: antibiotics, albumin infusion, and identification/treatment of precipitants.
Antibiotics — first-line:
- Cefotaxime 2 g intravenous (IV) every 8 hours for 5 days — gold-standard first-line therapy; third-generation cephalosporin with excellent gram-negative coverage; 5-day course equivalent to 10-day in randomized trials
- Ceftriaxone 2 g intravenous once daily — equivalent efficacy to cefotaxime; once-daily dosing is more convenient; widely used in clinical practice
- Both achieve 85–90% resolution of infection in community-acquired SBP
- Coverage is broadened to carbapenems (meropenem) for: healthcare-associated SBP, prior quinolone prophylaxis, prior broad-spectrum antibiotic exposure, known MDR colonization, or failure to respond to cephalosporins at 48 hours
Infection acquired in hospital: In a small randomized trial of 31 analyzed patients with SBP acquired in hospital, meropenem plus daptomycin resolved the infection in 86.7% against 25% for ceftazidime, though 90-day transplant-free survival did not differ significantly between the groups.
Antibiotic de-escalation: Once culture results return with sensitivities, treatment is narrowed to the narrowest appropriate agent. For pneumococcal SBP (gram-positive), amoxicillin-clavulanate or ampicillin can replace the cephalosporin.
Monitoring response:
- Repeat paracentesis at 48 hours — a PMN decrease of >25% is the expected response; failure to reach it suggests treatment failure, secondary peritonitis, or a resistant organism
- Clinical parameters: defervescence, improvement in encephalopathy, stabilization of renal function
Albumin Infusion: Preventing Kidney Injury
Co-administration of intravenous albumin with antibiotics is the single most important advance in SBP management since the introduction of third-generation cephalosporins. The landmark Sort et al. 1999 NEJM trial established this standard of care.
The Sort trial (NEJM 1999): 126 cirrhotic patients with SBP randomized to cefotaxime alone vs. cefotaxime + albumin (1.5 g/kg intravenous on day 1, then 1 g/kg intravenous on day 3). Results:
- Renal impairment: 33% (cefotaxime alone) vs. 10% (cefotaxime + albumin) — p=0.002
- In-hospital mortality: 29% vs. 10% — p=0.01
- 3-month mortality: 41% vs. 22% — p=0.03
- The benefit was concentrated in patients with serum creatinine >1 mg/dL, blood urea nitrogen (BUN) >30 mg/dL, or bilirubin >4 mg/dL at baseline — the highest-risk group
Current recommendation (European Association for the Study of the Liver, American Association for the Study of Liver Diseases, Asian Pacific Association for the Study of the Liver):
- Albumin 1.5 g/kg body weight intravenous at the time of diagnosis (day 1)
- Albumin 1.0 g/kg body weight intravenous on day 3
- Albumin is expensive; some guidelines restrict it to high-risk patients (creatinine >1 mg/dL, blood urea nitrogen >30, bilirubin >4) though many centers give it universally to all SBP patients given the mortality benefit
Mechanism: Albumin reduces systemic inflammation (lipopolysaccharide binding), improves circulatory dysfunction (oncotic pressure supports splanchnic vasoconstriction), and attenuates the hepatorenal syndrome (HRS) cascade. SBP-precipitated HRS carries >50% 30-day mortality — albumin significantly reduces this complication.
Prophylaxis and Prevention
Given the 40–70% 1-year recurrence rate after a first SBP episode and the high associated mortality, guidelines recommend antibiotic prophylaxis in several high-risk settings.
How strong the evidence is: A 2020 Cochrane network meta-analysis (29 trials, 3,896 people) rated the evidence low or very low certainty and reported considerable uncertainty about whether antibiotic prophylaxis helps and, if it does, which antibiotic helps most. In a 2018 French trial of 291 people with Child-Pugh class C cirrhosis, norfloxacin did not lower 6-month deaths in the main analysis (14.8% vs. 19.7% on placebo, P = .21), though it appeared to improve survival in those with ascitic protein below 15 g/L.
Secondary prophylaxis (after a first SBP episode):
- Norfloxacin 400 mg orally once daily — indefinitely or until liver transplantation; reduces SBP recurrence from ~68% to ~20% at 1 year (Gines et al.)
- Trimethoprim-sulfamethoxazole (TMP-SMX) double-strength once daily — acceptable alternative where norfloxacin unavailable; comparable efficacy
- Rifaximin 550 mg twice daily — a non-absorbable antibiotic that modulates the gut microbiome; its increasing use reflects concerns about quinolone resistance induction with long-term norfloxacin. In a 2022 open-label randomized trial of secondary prophylaxis, SBP recurred in 7% on rifaximin vs. 39% on norfloxacin (P = 0.004) and hepatic encephalopathy episodes were fewer (23.1% vs. 51.5%); in primary prophylaxis the two drugs were similar, and 180-day survival was similar in both settings. A 2017 systematic review called rifaximin a reasonable alternative to norfloxacin on moderate-quality evidence, mainly in hepatitis C cirrhosis.
- Norfloxacin over time: a 2020 meta-analysis of 12 randomized trials (1,626 patients) found norfloxacin still better than placebo at preventing SBP, but its effect against SBP, not against death, decreased over time (annual percent change 8.2% from 1992 to 2015).
Primary prophylaxis — acute gastrointestinal hemorrhage:
- Norfloxacin 400 mg twice daily for 7 days (or intravenous ceftriaxone 1 g/day for 7 days in advanced cirrhosis)
- Reduces SBP and bacteremia from ~20% to ~5% in cirrhotics with gastrointestinal bleeding; also reduces 90-day mortality
- Mandated in all guidelines — gastrointestinal bleeding is the highest-risk SBP precipitant
Primary prophylaxis — low ascitic protein + severe liver disease:
- Norfloxacin 400 mg daily was studied in people with ascitic total protein <15 g/L plus either advanced liver failure (Child-Pugh score ≥9 with serum bilirubin ≥3 mg/dL) or impaired kidney function (serum creatinine ≥1.2 mg/dL, blood urea nitrogen ≥25 mg/dL, or serum sodium ≤130 mEq/L)
- A 2007 randomized trial (68 patients) in this high-risk group: norfloxacin reduced the 1-year probability of SBP from 61% to 7% and of hepatorenal syndrome from 41% to 28%; 3-month survival was 94% vs. 62% and 1-year survival 60% vs. 48%
Liver transplantation: Definitive treatment for the underlying cirrhosis. SBP is a complication that raises the Model for End-Stage Liver Disease (MELD) score and can accelerate transplant listing eligibility. Survival after SBP is commonly treated as a reason for urgent evaluation for transplant listing.
Prognosis and Long-Term Outlook
SBP is a sentinel event in the natural history of cirrhosis, marking the onset or acceleration of liver decompensation. Even when the infection resolves with antibiotics, the underlying circulatory dysfunction and portal hypertension that enabled SBP remain — setting the stage for recurrence and further complications.
In-hospital outcomes:
- Resolution of infection with standard cefotaxime: 85–90%; in the 1999 albumin trial the infection resolved in 94% on cefotaxime and 98% on cefotaxime plus albumin (P = 0.36), so albumin’s benefit was to the kidneys and survival rather than to clearing the infection
- Acute kidney injury (AKI) with antibiotic alone (without albumin): 30–33%; in a 1994 series of 252 episodes, kidney impairment occurred in 33% and was the strongest independent predictor of death in hospital
- Acute kidney injury with cefotaxime + albumin protocol: 10%
- In-hospital mortality: 20–30% (all-comers); higher (>50%) in patients who develop HRS
Long-term outcomes:
- 1-year survival after first SBP: approximately 50–70% (variable by Child-Pugh class and transplant availability)
- 1-year SBP recurrence without prophylaxis: 40–70%
- 1-year SBP recurrence with norfloxacin prophylaxis: ~20%
- Median survival after first SBP episode historically: ~12–24 months without liver transplantation — this frames SBP as a transplant indication
Predictors of poor prognosis: MELD score >20 at time of SBP, development of acute kidney injury, serum creatinine >3 mg/dL at diagnosis, hepatic encephalopathy grade III–IV, bacteremia (positive blood cultures), and MDR organisms.
A first episode of SBP is commonly treated as a reason for urgent referral to a liver transplant center if the person is not already under transplant evaluation. For patients who are not transplant candidates, the focus shifts to maximizing quality of remaining life — optimizing encephalopathy management, continuing prophylaxis, and counseling about goals of care.
Key Research Papers
- — Sort P et al. "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis." New England Journal of Medicine 1999. — PubMed PMID: 10432325 (The landmark trial establishing albumin co-administration; reduced renal impairment from 33% to 10% and in-hospital mortality from 29% to 10%.)
- — Gines P et al. "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial." Hepatology 1990. — PubMed PMID: 2210673 (Secondary prophylaxis trial; norfloxacin reduced 1-year recurrence from 68% to 20%.)
- — Fernandez J et al. "Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis." Gastroenterology 2007. — PubMed PMID: 17854593 (Norfloxacin primary prophylaxis; reduced SBP from 61% to 7% at 1 year.)
- — Rimola A et al. "Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club." Journal of Hepatology 2000. — PubMed PMID: 10673079 (Classic International Ascites Club consensus establishing 5-day cefotaxime as standard of care.)
- — Praharaj DL et al. "Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial." Journal of Clinical and Experimental Hepatology 2022. — PubMed PMID: 35535057 (Open-label trial; secondary prophylaxis recurrence 7% vs. 39%.)
- — Sidhu GS et al. "Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review." BMJ Open Gastroenterology 2017. — PubMed PMID: 28944070 (Four studies; moderate-quality evidence, mainly in hepatitis C cirrhosis.)
- — Tandon P, Garcia-Tsao G. "Bacterial infections, sepsis, and multiorgan failure in cirrhosis." Seminars in Liver Disease 2008. — PubMed PMID: 18293275 (Review of infection pathophysiology in cirrhosis and systemic consequences.)
- — European Association for the Study of the Liver. "EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis." Journal of Hepatology 2018. — PubMed PMID: 29653741 (European Association for the Study of the Liver guidelines including SBP management recommendations.)
- — Runyon BA. "Management of adult patients with ascites due to cirrhosis." Hepatology 2004. — PubMed PMID: 14999706 (American Association for the Study of Liver Diseases practice guideline; criteria for SBP vs. secondary peritonitis and diagnostic paracentesis indications.)
- — Bernardi M et al. "Albumin in decompensated cirrhosis: new concepts and perspectives." Gut 2020. — PubMed PMID: 32102926 (Mechanism of albumin beyond volume expansion — LPS binding, anti-inflammatory effects.)
- — Follo A et al. "Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis." Hepatology 1994. — PubMed PMID: 7982650 (Natural history of AKI complicating SBP without albumin.)
- — Koulaouzidis A et al. "Leucocyte esterase reagent strips for the diagnosis of spontaneous bacterial peritonitis: a systematic review." European Journal of Gastroenterology & Hepatology 2008. — PubMed PMID: 19047835 (Seventeen studies, too heterogeneous to pool.)
- — Nousbaum JB et al. "Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis." Hepatology 2007. — PubMed PMID: 17464969 (Multicenter study of 2,123 paracenteses.)
- — Chinnock B et al. "Sensitivity of a bedside reagent strip for the detection of spontaneous bacterial peritonitis in ED patients with ascites." American Journal of Emergency Medicine 2019. — PubMed PMID: 30737002 (Emergency department cohort, 635 fluid analyses.)
- — Kim JJ et al. "Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis." American Journal of Gastroenterology 2014. — PubMed PMID: 25091061 (Two centers, 239 patients.)
- — Piano S et al. "The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial." Hepatology 2016. — PubMed PMID: 26084406 (Meropenem plus daptomycin vs. ceftazidime.)
- — Komolafe O et al. "Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis." Cochrane Database of Systematic Reviews 2020. — PubMed PMID: 31978256 (29 trials, 3,896 participants.)
- — Moreau R et al. "Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis." Gastroenterology 2018. — PubMed PMID: 30144431 (Double-blind trial, 291 patients.)
- — Mücke MM et al. "Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis." Clinical and Translational Gastroenterology 2020. — PubMed PMID: 32955202 (12 trials, 1,626 patients.)
- — Alhumaid S et al. "Proton pump inhibitors use and risk of developing spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis." Gut Pathogens 2021. — PubMed PMID: 33741033 (23 studies, 10,386 patients.)